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Abstract 29 
Context: Systemic sclerosis (SSc) is a connective tissue disease of unknown aetiology and several 30 
studies reported its association with thyroid autoimmune disorders. No study has evaluated 31 
longitudinally the incidence of new cases of thyroid autoimmunity and dysfunction in SSc patients. 32 
Objective: To evaluate the incidence of new cases of clinical and subclinical thyroid dysfunction in a 33 
wide group of women with SSc, versus an age- and gender-matched control group from the same 34 
geographic area. 35 
Design and Patients or Other Participants: After exclusion of sclerodermic patients with thyroid 36 
dysfunction (n=55) at the initial evaluation, the appearance of new cases of thyroid disorders was 37 
evaluated in 179 patients and 179 matched controls, with similar iodine intake (median follow-up 73 38 
months in SSc versus 94 in controls). 39 
Results: A high incidence (P < 0.05) of new cases of hypothyroidism, thyroid dysfunction, anti–40 
thyroperoxidase antibody positivity, appearance of a hypoechoic thyroid pattern in sclerodermic 41 
patients (15.5, 21, 11, 14.6/1000 patients per year; respectively) versus controls was shown. A logistic 42 
regression analysis showed that in SSc patients the appearance of hypothyroidism was related to a 43 
border line high initial thyroid stimulating hormone, anti–thyroperoxidase antibody positivity, a 44 
hypoechoic and small thyroid. 45 
Conclusions: Our study shows a high incidence of new cases of hypothyroidism and thyroid 46 
dysfunction in female sclerodermic patients. Female sclerodermic patients, who are at high risk [a 47 
border line high (even if in the normal range) thyroid stimulating hormone, positive anti–48 
thyroperoxidase antibody, hypoechoic and small thyroid] should have periodically thyroid function 49 
follow-up. 50 
51 
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Introduction 51 
Discordant results on the association between thyroid autoimmunity and Systemic sclerosis (SSc)  52 
have been reported (1-5). However, no study has evaluated longitudinally the incidence of new cases 53 
of thyroid autoimmunity and dysfunction in SSc patients. 54 
The aim of our study was to evaluate the incidence of new cases of clinical and subclinical thyroid 55 
dysfunction in a wide group of SSc women. 56 
 57 
Patients and Methods 58 
Two hundred and thirty-four female SSc patients (6,7) consecutively referred to the Rheumatology 59 
Units of the University of Pisa and Modena (from 1993 to 2008) underwent a thyroid evaluation (7).  60 
Among the 234 SSc patients, those with subclinical or clinical hypothyroidism, subclinical 61 
hyperthyroidism or Graves’ disesase, were excluded. One hundred seventy-nine SSc patients without 62 
thyroid dysfunction were eligible for the longitudinal study (43 from Modena). They were studied 63 
again, at least 1 year after the initial evaluation, one or more times. The mean follow-up period from 64 
the initial evaluation was 68 months (range 12-175 months, median 73 months).  65 
Skin sclerosis was observed in all patients (diffuse 43, or limited 57%; visceral involvement included: 66 
peripheral vascular system, 93%; gastrointestinal system, 55%; lung, 64%; joint/tendons, 24%; heart, 67 
27%; kidney, 13%). The prevalence of autoantibodies (2,3) was: antinuclear 92%, anticentromere 68 
35%, anti-topoisomerase I (anti-Scl-70) 44%. 69 
Each of the 179 female SSc patients eligible for the study was gender- and age-matched, one-to-one 70 
with a control group, without thyroid dysfunction, of the background population from the same 71 
geographic area (North-West Tuscany) (8). This control group was extracted from a larger sample of 72 
1081 subjects in a population-based survey of thyroid disorders, who were initially studied in 1994 73 
and subsequently reevaluated (by thyroid function, autoantibodies and ultrasonography) in 2002-2003 74 
(see above).  75 
Since thyroid autoimmunity is affected by iodine intake (9), morning urinary samples were collected 76 
from 97 SSc patients and 108 controls. Urinary iodine excretion (UIE) was measured by a 77 
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colorimetric method (10). The results were calculated as micrograms of iodine per liter of urine and 78 
are expressed as median and interquartile range (IR). 79 
The mean follow-up period from the initial evaluation was 95 months (range 87-106 months, median 80 
94 months). All SSc patients and controls were reevaluated, by: a- physical examination; b- thyroid 81 
ultrasonography, as previously reported (11); c- thyroid nodules with a diameter > 10 mm were 82 
submitted to ultrasonography-guided fine-needle aspiration (FNA) (11); d- circulating free T3 (FT3) 83 
and free T4 (FT4) (AMERLEX-MAB FT3/FT4 Kit; Amersham, UK), TSH (reference range 0.3-3.6 84 
µU/mL) (DiaSorin, USA), anti–thyroperoxidase (AbTPO) and anti–thyroglobulin (AbTg) antibodies 85 
(ICN Pharmaceuticals, USA; positivity > 100 IU/mL). Anti-TSH-receptor antibodies (TRAb) were 86 
measured in patients with hyperthyroidism (Radim, Italy; normal range 0-1 IU/mL). 87 
If thyroid dysfunction appeared during the follow-up, SSc patients were appropriately treated and 88 
excluded from a further evaluation. 89 
The study was approved by the institutional ethic committee, and all subjects gave their informed 90 
written consent to participate.  91 
Mean group values were compared using one-way ANOVA for normally distributed variables, 92 
otherwise by the Mann-Whitney U test. The χ2 test was used to compare categorical variables. A 93 
logistic regression analysis was performed including age, smoking, TSH, AbTPO positivity, AbTg 94 
positivity, thyroid hypoechogenicity (presence/absence), thyroid volume (all at the start of evaluation) 95 
as independent variables, and hypothyroidism at last evaluation as dependent variable.  96 
 97 
Results    98 
Longitudinal study 99 
After the exclusion of patients with thyroid dysfunction and thyroid cancer (55 patients), the thyroid 100 
status of SSc patients entering the longitudinal study and matched controls is reported in Table 1. 101 
UIE in SSc patients and in controls was not significantly different (median 87.0 µg/L, IR 39.0–143.5 102 
µg/L; median 79.0 µg/L, IR 34.3–138.6 µg/L, respectively; P = ns).  103 
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The prevalence of subjects with positive AbTPO, thyroid hypoechoic pattern, and thyroid volume < 6 104 
mL were significantly higher in the SSc group than in controls (Table 1), while TSH was slightly but 105 
significantly higher in SSc patients. On the whole, indices of thyroid autoimmunity (AbTg, or 106 
AbTPO, or ultrasonographic diagnosis of thyroiditis) were significantly more frequent in SSc than in 107 
controls. No other statistically significant difference was observed at basal evaluation.  108 
At the last evaluation (after a median of 73 and 94 months, respectively in SSc and controls: P < 0.01, 109 
ANOVA) TSH levels and AbTPO titers were significantly higher in SSc than in controls (Table 1). 110 
Subclinical hypothyroidism was significantly more common in SSc than in controls, while clinical 111 
hypothyroidism did not reach the significance. Two cases of Graves’ disease were observed in SSc 112 
patients, while no case was observed in controls. The prevalence of subclinical hyperthyroidism was 113 
similar in SSc and controls. On the whole the prevalence of thyroid dysfunction (subclinical or 114 
clinical hypo- and hyper-thyroidism) was significantly more frequent in SSc patients (Table 1). The 115 
prevalence of subjects with positive AbTPO, thyroid hypoechoic pattern, and thyroid volume < 6 mL 116 
were significantly higher in the SSc group than in controls. Two cases of papillary thyroid cancer 117 
(suspected by FNA and confirmed by histology) were observed in SSc, while none in controls (Table 118 
1).  119 
The prevalence and the incidence of new cases of thyroid disorders is reported in Table 2. Thyroid 120 
dysfunction, subclinical hypothyroidism, hypothyroidism, AbTPO positivity and a thyroid hypoechoic 121 
pattern were significantly more frequent in SSc than in controls.  122 
Among the 23 patients who developed thyroid dysfunction during the follow-up, 11 (48%) showed 123 
cutaneous diffuse SSc and 12 (52%) the limited variant; visceral involvement included: peripheral 124 
vascular system, 91%; gastrointestinal system, 52%; lung, 65%; joint/tendons, 22%; heart, 30%; 125 
kidney, 9%; any statistical signicant difference was observed with respect to SSc patients without 126 
thyroid dysfunction. The prevalence of autoantibodies was: antinuclear 96%, anticentromere 30%, 127 
anti-Scl-70 48%; no statistical significant difference was observed with respect to SSc patients 128 
without thyroid dysfunction. In fact, the proportions of antinuclear, anticentromere, anti-Scl-70 129 
autoantibodies in the SSc group who developed thyroid dysfunction (98%, 28%, 52%, respectively), 130 
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were not significantly different from the corresponding proportions in the SSc group who did not 131 
develop thyroid dysfunction (95%, 31%, 45%; respectively).  132 
In SSc patients at the end of the follow-up, hypothyroidism was significantly associated with presence 133 
of AbTPO-positivity (P < 0.0001), a small thyroid volume (< 6 mL) (P < 0.0001), and a hypoechoic 134 
pattern (P < 0.0001) (all by χ2); no relationship was found with the other thyroid parameters. 135 
Moreover, no significant association was observed among the cutaneous or visceral involvement or 136 
the presence of SSc specific autoantibodies and thyroid autoantibodies, or others of the studied 137 
parameters.  138 
The number of euthyroid SSc patients and controls who were “thyroid autoantibody negative and with 139 
a nodule-free thyroid of normal echogenicity” (“clean”) were respectively 83, and 75. The number of 140 
new cases of subclinical hypothyroidism or hyperthyroidism in these “clean” SSc patients were 3, and 141 
1, respectively (4/83=5%), while in “clean” controls they were, 1 and 0, respectively (1/75=1%); the 142 
difference was not statistically significant. No other dysfunctions were observed in the “clean” 143 
patients.  144 
In SSc women, the logistic regression analysis [in a model including, age, smoking, TSH value, 145 
AbTPO positivity, AbTg positivity, thyroid hypoechogenicity (presence/absence), thyroid volume (all 146 
at the start of evaluation) as independent variables, and hypothyroidism at last evaluation as 147 
dependent variable] shows that the appearance of hypothyroidism was related to a border line high 148 
initial TSH [coefficient, 0.859; Exp(coef), 2.361; 95% lower, 1.022; 95% upper, 5.455; P = 0.0443], 149 
AbTPO positivity [coefficient, 0.735; Exp(coef), 2.085; 95% lower, 1.154; 95% upper, 3.767; P = 150 
0.0150], a hypoechoic pattern [coefficient, 0.919; Exp(coef), 2.506; 95% lower, 1.480; 95% upper, 151 
4.245; P = 0.0006], and a small thyroid volume [coefficient, -0.155; Exp(coef), 0.857; 95% lower, 152 
0.806; 95% upper, 0.911; P < 0.0001]. 153 
 154 
Discussion 155 
Our study demonstrates a high incidence of new cases of hypothyroidism, thyroid dysfunction, 156 
AbTPO positivity, and appearance of a hypoechoic thyroid pattern in SSc women (15.5, 21, 11, 157 
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14.6/1000 SSc per year; respectively) in comparison with the control group, with similar urinary 158 
iodine excretion.  159 
It should be stressed that the incidence of new cases of hypothyroidism and AbTPO in the control 160 
group was similar to that observed in other epidemiological studies (12-14), suggesting that the 161 
control group is not biased, versus a low thyroid autoimmunity.  162 
Interestingly, mean TSH value, the percentage of antithyroid antibodies, thyroid hypoechoic pattern 163 
and small thyroid volume, were all significantly higher in SSc than in controls, in agreement with 164 
other studies, and our previous transversal study (3). 165 
The results of the logistic regression analysis show that in SSc women the appearance of 166 
hypothyroidism was related to a border line high (even if in the normal range) TSH, the presence of 167 
AbTPO positivity, a hypoechoic pattern, and a small thyroid volume, in agreement with the results of 168 
other studies in the general population (12-14).  169 
The baseline significant  differences between SSc patients and controls, in the above mentioned 170 
parameters, may account at least in part for the higher incidence of hypothyroidism in the SSc group. 171 
However, interestingly, the prevalence of thyroid dysfunction in SSc patients and controls who were 172 
“thyroid autoantibody negative and with a nodule-free thyroid of normal echogenicity” (“clean” SSc 173 
patients) at the end of the study (5%) was higher than in “clean” controls (1%), even if the statistical 174 
significance was not reached. This may suggest that also “clean” SSc patients should be periodically 175 
surveyed for thyroid function. 176 
The association of autoimmune disorders is a well known phenomenon (15). The pathogenetic base of 177 
this association is under debate. Many evidence accumulated from animal models and available in 178 
human diseases favor a prevalent Th1 lymphokine profile in target organs of patients with chronic 179 
autoimmune thyroiditis, or Graves' ophthalmopathy (16), in the initial phase of these disorders. 180 
Similarly, a prevalent Th1 immune reactivity is present in the initial phase of SSc, that switches to a 181 
prevalent Th2 immune response later (17-20). This prevalence of the Th1 immune reactivity in the 182 
initial phase of both SSc, and autoimmune thyroiditis, might be the common base that, under the 183 
combined action of genetic and environmental conditions, may lead to the appearance of autoimmune 184 
phenomena that involve different organs in the same subject (15). 185 
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In conclusion, our study shows a high incidence of new cases of hypothyroidism, thyroid dysfunction, 186 
AbTPO positivity, and appearance of a hypoechoic thyroid pattern in SSc women in comparison with 187 
the control group. However, similar studies performed in other European and non-European countries 188 
are necessary to confirm these results. Risk factors for the development of thyroid dysfunction are a 189 
border line high (even if in the normal range) TSH, the presence of AbTPO positivity, a hypoechoic 190 
pattern, and a small thyroid volume. Thyroid function and ultrasonography should be tested as a part 191 
of the clinical profile in female SSc patients. Those who are at high risk [a border line high (even if in 192 
the normal range) TSH, positive AbTPO, hypoechoic and small thyroid] should have periodically 193 
(approximately every year) thyroid function follow-up and appropriate treatment in due course. 194 
195 
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Table 1. Comparison of thyroid status at the initial, or at the last evaluation, between Systemic 273 
Sclerosis (SSc) patients and matched controls. 274 
 Initial thyroid status  Last evaluation 
 SSc Controls P  SSc Controls P 
N° 179 179   179 179  
Age, y (SD) 50 (13) 52 (10) ns  56 (13) 60 (10) ns 
Gender (female) 179 179 ns  179 179 ns 
TSH, µU/mL (SD) 2.1 (0.7)b 1.1 (0.6) 0.043a  2.9 (4.1)b 1.3 (1.1) 0.018a 
FT4, pmol/L (SD) 115 (4.1) 122 (3.1) ns  110 (4.6) 121 (3.4) ns 
FT3, pmol/L (SD) 4.7 (1.9) 5.0 (1.1) ns  4.5 (1.9) 4.9 (1.2) ns 
AbTg, IU/mL (SD) 72 (134) 27 (85) ns  94 (215) 36 (96) ns 
AbTPO, IU/mL (SD) 91 (169)b 15 (35) 0.026a  125 (256)b 23 (52) 0.013a 
Subclinical hypothyroidism 0% 0% ns  7.8% 1.7% 0.006c 
Clinical hypothyroidism 0% 0% ns  1.7% 0.56% ns 
Subclinical  hyperthyroidism 0% 0% ns  2.2% 1.7% ns 
Graves’ disease 0% 0% ns  1.1% 0% ns 
Thyroid dysfunctions 0% 0% ns  13% 4% 0.001c 
AbTg+ 11% 7% ns  13% 9% ns 
AbTPO+ 21% 12% 0.022c  27% 13% 0.002c 
Hypoechoic pattern 23% 12% 0.008c  32% 15% <0.0001c 
Thyroid autoimmunity 24% 12% 0.002c  34% 16% <0.001c 
Thyroid volume, mL (SD) 11 (10) 14 (13) 0.044a  10 (11) 14 (12) 0.037a 
Thyroid volume > 20 mL 11% 13% ns  11% 14% ns 
Thyroid volume < 6 mL 12% 5% 0.015c  16% 6% 0.004c 
Thyroid nodules 39% 43% ns  44% 50% ns 
Thyroid cancer 0% 0% ns  1.1% 0% ns 
TSH = thyroid stimulating hormone; AbTPO = anti-thyroperoxidase antibody; AbTPO+ = anti-275 
thyroperoxidase antibodies >100 IU/ml; AbTg = anti-thyroglobulin antibody; AbTg+ = anti-276 
thyroglobulin antibodies >100 IU/ml; FT3 = free triiodothyronine; FT4 = free thyroxine; AbTg+ or 277 
AbTPO+ or ultrasonographic diagnosis of thyroiditis = thyroid autoimmunity. a = ANOVA. b = TSH 278 
levels and AbTPO titers were significantly higher in SSc than in controls. c = χ2. Conversion factors 279 
for SI units: FT4 = 12.871; FT3 = 0.0154. 280 
 281 
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Table 2. New cases and incidencea of thyroid disorders in Systemic Sclerosis at the last 282 
evaluation. 283 
 
 
Systemic Sclerosis  
number new cases 
(incidence) 
Controls 
number new cases 
(incidence) 
Pb 
 
Subclinical hypothyroidism 14 (12.8) 3 (2.1) 0.006 
Clinical hypothyroidism 3 (2.7) 1 (0.7) ns 
Hypothyroidism 17 (15.5) 4 (2.8) 0.003 
Subclinical  hyperthyroidism 4 (3.6) 3 (2.1) ns 
Graves’ disease 2 (1.8) 0 (0) ns 
Hyperthyroidism 6 (5.4) 3 (2.1) ns 
Thyroid dysfunction 23 (21) 7 (4.2) 0.001 
AbTg+ 4 (3.6) 3 (2.1) ns 
AbTPO+ 11 (11) 3 (2.8) 0.04 
Hypoechoic pattern 16 (14.6) 5 (3.5) 0.013 
Thyroid volume > 20 mL 0 (0) 2 (1.4) ns 
Thyroid volume < 6 mL 6 (5.4) 2 (1.4) ns 
Thyroid nodules 9 (8.2) 12 (8.5) ns 
a Incidence is reported in parenthesis. Incidence = [incidence = number of new cases / patients (179) x 284 
years of follow-up (73 months = 6.1 years) = number of new events / 1092 patients per year)] and 285 
matched controls (C) [incidence = number of new cases / subjects (179) x years of follow-up (94 286 
months = 7.8 years) = number of new events / 1396 patients per year)].  287 
b = χ2 (number of new cases). 288 
AbTPO = anti-thyroperoxidase antibody; AbTPO+ = anti-thyroperoxidase antibodies >100 IU/mL; 289 
AbTg = anti-thyroglobulin antibody; AbTg+ = anti-thyroglobulin antibodies >100 IU/mL. 290 
 291 
 292 
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